Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular …
XQ Liu, YF Zhang, HY Ding, MM Yan, MK Zhong… - BMJ open, 2022 - bmjopen.bmj.com
Introduction Rivaroxaban is one of the most commonly used non-vitamin K antagonists for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular …
XQ Liu, YF Zhang, HY Ding, MM Yan, MK Zhong… - BMJ Open, 2022 - europepmc.org
Introduction Rivaroxaban is one of the most commonly used non-vitamin K antagonists for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular …
XQ Liu, YF Zhang, HY Ding, MM Yan… - BMJ …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Rivaroxaban is one of the most commonly used non-vitamin K antagonists for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
[PDF][PDF] Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non …
XQ Liu, YF Zhang, HY Ding, MM Yan, MK Zhong… - scholar.archive.org
Introduction Rivaroxaban is one of the most commonly used non-vitamin K antagonists for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular …
L Xiao-Qin, Z Yu-Fei, D Hong-Yan, Y Ming-Ming… - BMJ …, 2022 - search.proquest.com
Introduction Rivaroxaban is one of the most commonly used non-vitamin K antagonists for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
stroke prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular …
XQ Liu, YF Zhang, HY Ding, MM Yan, MK Zhong… - BMJ Open, 2022 - europepmc.org
Rivaroxaban is one of the most commonly used non-vitamin K antagonists for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …
prevention in patients with non-valvular atrial fibrillation (NVAF). Different individual …